AbbVie declares its $1.73 quarterly dividend and reports positive Phase 3 data for Qulipta in menstrual migraine

ABBV declared a quarterly dividend of $1.73 per share on September 10, 2026, payable November 16 to shareholders of record on October 15. That is a continuation of the current rate rather than a new increase: AbbVie raised the quarterly payout to $1.73 from $1.64 back in January 2026, and this declaration holds it. The annualized rate is $6.92, a yield of about 2.7% at recent prices, supported by a payout ratio of 49.5% and a forward payout ratio of 42.8%. The company has now raised its dividend in 53 consecutive years.

The clinical news is the more consequential item. The Phase 3 LUNA trial of atogepant, sold as Qulipta, met its primary endpoint and all eight secondary endpoints in perimenstrual migraine, with a reduction of 0.80 migraine days versus placebo, 1.20 against 0.40, at p<0.0001. This is topline data supporting a planned regulatory submission, not an approval, and should not be read as one.

The commercial logic behind a menstrual-migraine indication is about expanding an existing franchise rather than opening a new one. Qulipta is already marketed in preventive migraine, so a dedicated perimenstrual label would widen the addressable population inside a drug that is already launched, promoted and reimbursed. That is a cheaper form of growth than a new molecule and it lands in the part of AbbVie's portfolio meant to offset Humira erosion.

For context on the base business, AbbVie's most recent quarter showed earnings per share of $3.65 on revenue of $16.99 billion. Shares closed at $254.99 on September 10, up 1.6%, a move coverage attributes to a combination of the dividend declaration, the trial readout and a price-target increase from HSBC rather than to any one of them. What to watch is the timing of the regulatory submission for the new indication, since that is the step that converts trial data into label-expansion revenue.